MedTrace Logo

Zalutumumab in Non-curable Patients With SCCHN

NCT00542308 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2023-08-03

Study results available
· View outcomes & findings →

Summary

Treatment, In combination with BSC, Open-label, Single arm, Efficacy Study.

Conditions

Interventions

DRUG

Zalutumumab

Individual dose titration weekly i.v. doses

Sponsors & Collaborators

  • Genmab

    lead INDUSTRY

Principal Investigators

  • Steen Lisby, MD · Genmab A/S, Bredgade 34, DK-1260 Copenhagen K, Denmark

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2011-08-31
Completion
2011-08-31

Countries

  • United States
  • Austria
  • Chile
  • Colombia
  • Czechia
  • Germany
  • Israel
  • Italy
  • Peru
  • Portugal
  • Slovakia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00542308 on ClinicalTrials.gov